Los Angeles, CA -- (SBWIRE) -- 03/08/2013 -- MANNKIND CORPORATION (NASDAQ:MNKD) is a development-stage biopharmaceutical organization. The Business is targeted on the development, growth and commercialization of healing products for illnesses such as diabetic issues and melanoma. The Business's item applicant, AFREZZA (insulin human) breathing dust, is blood insulin that is in late-stage medical research for the treatment of grownups with kind I or kind II diabetic issues for the control of hyperglycemia.
The AFREZZA breathing dust is based on a type of prospective of hydrogen (pH)-sensitive natural elements. AFREZZA uses its Technosphere ingredients technological innovation. As of Dec 31, 2011, MannKind had not produced any item earnings.
MannKind Corporation (NASDAQ:MNKD) shares increased 6.76% to $3. The company, on Feb. 11, reported financial results for the fourth quarter and year ended December 31, 2012. For the fourth quarter of 2012, total operating expenses were $33.5 million, compared to $30.6 million for the same quarter of 2011, an increase of $2.9 million. Net loss for fiscal year 2012 was $(169.4) million, or $(0.94) per share, compared to net loss of $(160.8) million, or $(1.32) per share based on 121.8 million weighted average shares outstanding for fiscal year 2011.
Is MNKD Ready To Jump Again After The Solid Momentum? Get Free Trend Analysis Here
Neither PennyStocksUpdate.biz nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor or broker dealer in any jurisdiction whatsoever and none of the information provided by PennyStocksUpdate.biz, owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or an investment recommendation.PennyStocksUpdate.biz makes no recommendation that the securities of the companies profiled should be purchased, sold or held by individuals or entities that learn of the profiled companies through PennyStocksUpdate.biz. Investing in securities is speculative and carries a high degree of risk and no investment should be made unless you can afford to lose your entire investment. It is possible that an investor's entire investment may be lost or impaired due to the speculative nature of the companies profiled. Please consult a broker before purchasing or selling any securities viewed on or mentioned here in..
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-321-1250 (International)